In conclusion, our results strongly support ERG as a novel regulator of EC-specific targets and pathways, including canonical TGF-β-SMAD, Notch, and NO pathways, by modulating a differential progression (i.e., fibrotic or calcified) of AAA in BAV and TAV aortas. The gene discussed is ERG; the disease is triple-A syndrome.